We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESM
576
DELISTED
ESM Acquisition Corporation
ESM
| $15.1M | 0.03% |
1,497,129
| – | – |
|
|
GXII
577
DELISTED
GX Acquisition Corp. II Class A Common Stock
GXII
| $15M | 0.03% |
1,499,883
| – | – |
|
|
AIRJ
578
Montana Technologies Corp
AIRJ
$302M
| $15M | 0.03% |
1,485,458
| – | – |
|
579
Concentrix
CNXC
$1.36B
| $14.9M | 0.03% |
112,241
-178,620
| -61% | -$21.7M |
|
|
CIVI
580
DELISTED
Civitas Resources
CIVI
| $14.9M | 0.03% |
257,900
+231,843
| +890% | +$14.9M |
|
581
Ambarella
AMBA
$2.99B
| $14.8M | 0.03% |
180,366
-53,218
| -23% | -$3.54M |
|
582
Shift4
FOUR
$3.84B
| $14.8M | 0.03% |
264,672
+207,179
| +360% | +$9.79M |
|
|
ICNC
583
DELISTED
Iconic Sports Acquisition Corp.
ICNC
| $14.8M | 0.03% |
1,430,668
| – | – |
|
584
Paylocity
PCTY
$6.71B
| $14.8M | 0.03% |
76,145
+62,103
| +442% | +$13.3M |
|
|
MRSN
585
DELISTED
Mersana Therapeutics
MRSN
| $14.8M | 0.03% |
100,959
+79,820
| +378% | +$13.5M |
|
586
Perrigo
PRGO
$1.4B
| $14.7M | 0.03% |
+432,155
| New | +$15.2M |
|
|
AGGR
587
DELISTED
Agile Growth Corp
AGGR
| $14.7M | 0.03% |
1,458,108
| – | – |
|
|
VGR
588
DELISTED
Vector Group Ltd.
VGR
| $14.7M | 0.03% |
1,236,266
+445,740
| +56% | +$4.71M |
|
589
Fiverr
FVRR
$376M
| $14.6M | 0.03% |
502,309
+62,674
| +14% | +$1.97M |
|
590
Danaos Corp
DAC
$2.55B
| $14.6M | 0.03% |
277,608
-139,923
| -34% | -$7.88M |
|
591
Snowflake
SNOW
$92.9B
| $14.6M | 0.03% |
+101,734
| New | +$15.5M |
|
|
SDST
592
Stardust Power Inc
SDST
$16.7M
| $14.6M | 0.03% |
144,015
| – | – |
|
593
PUT
Wells Fargo
WFC
$261B
| $14.5M | 0.03% |
351,900
+149,800
| +74% | +$6.63M |
|
594
PUT
Goldman Sachs
GS
$313B
| $14.5M | 0.03% |
42,300
+34,700
| +457% | +$12.1M |
|
|
ACRO
595
DELISTED
Acropolis Infrastructure Acquisition Corp
ACRO
| $14.5M | 0.03% |
1,458,219
| – | – |
|
596
Clearway Energy Class C
CWEN
$5B
| $14.5M | 0.03% |
+454,403
| New | +$15.3M |
|
597
Flowserve
FLS
$9.25B
| $14.4M | 0.03% |
+470,308
| New | +$13.7M |
|
|
CLAA
598
DELISTED
Colonnade Acquisition Corp. II
CLAA
| $14.4M | 0.03% |
1,431,353
| – | – |
|
599
RingCentral
RNG
$4.05B
| $14.4M | 0.03% |
407,123
-52,460
| -11% | -$1.88M |
|
600
Aflac
AFL
$63.9B
| $14.4M | 0.03% |
199,769
-881,806
| -82% | -$59M |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.